20 (AIDX) Research & Development (2025 - 2026)
20's (AIDX) quarterly Research & Development came in at $257632.0 in Q2 2026, up 32.72% on a YoY basis from $194124.0 in Q2 2025, and up 67.86% quarter-over-quarter from $153482.0 in Q1 2026.
Powered by 
Analysis
20 (AIDX) Research & Development (2025 - 2026) Analysis & Trends
20 (AIDX) has reported Research & Development for 2 consecutive years, with $257632.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Research & Development rose 32.72% year-over-year to $257632.0; the trailing twelve-month figure through Jun 2026 stood at $742069.0 (changed N/A YoY), and the FY2025 full-year result was $592569.0, down 53.04% from the prior year.
- Research & Development advanced to $257632.0 in Q2 2026 per AIDX's latest filing, from $153482.0 in the prior quarter.
- Across five years, Research & Development topped out at $257632.0 in Q2 2026 and bottomed at $136831.0 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Natera | 46.91 Bn | 45.81 Bn | 486.15 Mn | 228.07 Mn |
| 2 | Labcorp Holdings | 26.24 Bn | 26.10 Bn | 1.11 Bn | - |
| 3 | Quest Diagnostics | 25.94 Bn | 25.31 Bn | 1.03 Bn | - |
| 4 | Guardant Health | 21.78 Bn | 20.72 Bn | 219.03 Mn | 189.95 Mn |
| 5 | Tempus AI | 11.22 Bn | 10.40 Bn | 274.25 Mn | 52.64 Mn |
| 6 | Caris Life Sciences | 6.96 Bn | 6.17 Bn | 182.38 Mn | 53.76 Mn |
| 7 | Sotera Health | 5.25 Bn | 4.89 Bn | 177.96 Mn | - |
| 8 | BillionToOne | 4.69 Bn | 4.14 Bn | 77.11 Mn | 17.32 Mn |
| 9 | iRhythm Holdings | 3.98 Bn | 3.39 Bn | 163.21 Mn | 19.84 Mn |
| 10 | 20 | 6.09 Mn | 1.55 Mn | 304,727.00 | 257,632.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 257,632.00 |
| Mar 31, 2026 | 153,482.00 |
| Jun 30, 2025 | 194,124.00 |
| Mar 31, 2025 | 136,831.00 |